Bortezomib, which may suppress multiple inflammatory cytokines through inhibiting NF-κB activation, hence appears to be a better anti-inflammatory agent in treatment of autoimmune uveitis than TNF-α antagonists. The gene discussed is NFKB1; the disease is autoimmune uveitis.